


## Improving the T:N Ratio is Especially Important in Complex Patients

A comprehensive real-world evidence study analyzed TACE and TARE claims between 2019 and 2022.<sup>1</sup> The study showed that Interventional Radiologists choose the TriNav® Infusion System to treat their most challenging patients – because improving the T:N ratio is especially important in complex patients.

What does a complex patient profile look like? It can include:

### Prior Embolization


Previously embolized tumors can be more difficult to visualize and penetrate due to regions of necrosis and damaged vasculature.<sup>2</sup>



Residual disease following TACE<sup>3</sup>

### Large Tumors


Lack of particle penetration may cause poor response to embolization therapies in patients with large (>5-cm) tumors.<sup>4</sup>



Pre-treatment CT showing 7x6-cm, biopsy-proven HCC

### Multi-Focal Disease


It can be difficult to deliver adequate treatment while minimizing injury to normal liver in patients with multiple tumors.<sup>5</sup>



Multi-focal, poorly differentiated cholangiocarcinoma

### Borderline Liver Function


In patients with borderline liver function, the challenge is to deliver an effective treatment while preserving adequate healthy liver tissue.<sup>6</sup>



Typical HCC in a patient with chronic hepatitis C<sup>7</sup>

### Hypovascular Tumors

It can be challenging to achieve adequate particle penetration into hypovascular tumors.<sup>8</sup>



Metastatic renal cell carcinoma with hypovascular liver metastases

Multiple clinical studies have shown that TriNav's Pressure-Enabled Drug Delivery™ (PEDD™) approach improves the T:N ratio<sup>9</sup> by increasing therapeutic delivery to the tumor<sup>10</sup> while simultaneously decreasing non-target delivery.<sup>11</sup>

Click [here](#) to learn more about the real-world and clinical evidence that support the use of PEDD to treat complex patients, or click [here](#) to request an appointment with a representative.

#### Indications For Use

The TriNav and TriNav LV Infusion Systems are intended for use in angiographic procedures. They deliver radiopaque media and therapeutic agents to selected sites in the peripheral vascular system.<sup>12,13</sup>

#### Contraindications

The TriNav and TriNav LV Infusion Systems are not indicated for use in the vasculature of the central nervous system (including the neurovasculature) or central circulatory system (including the coronary vasculature).<sup>12,13</sup>

#### Rx Only

For the safe and proper use of the TriNav and TriNav LV Infusion Systems, refer to their individual Instructions for Use.

#### References

1. Cook K, Gupta D, Liu Y, et al. Real-world evidence of pressure-enabled drug delivery for trans-arterial chemoembolization and radioembolization among patients with hepatocellular carcinoma and liver metastases. *Curr Med Res Opin.* 2024;40(4):591-598.
2. Chen S, Peng Z, Zhang Y, et al. Lack of response to transarterial chemoembolization for intermediate-stage hepatocellular carcinoma: abandon or repeat? *Radiology.* 2021;298(3):680-692.
3. Gupta P, Kalra N, Gulati A, et al. Response assessment following image-guided therapy of hepatocellular carcinoma. *J Clin Interv Radiol ISVIR.* 2020;4(02):088-097.
4. Higuchi T, Kikuchi M, Okazaki M. Hepatocellular carcinoma after transcatheter hepatic arterial embolization. A histopathologic study of 84 resected cases. *Cancer.* 1994;73(9):2259-2267.
5. Tomozawa Y, Jahangiri Y, Pathak P, et al. Long-term toxicity after transarterial radioembolization with yttrium-90 using resin microspheres for neuroendocrine tumor liver metastases. *J Vasc Interv Radiol.* 2018;29(6):858-865.
6. Jeschke M, Ludwig JM, Leyh C, et al. Bilobar radioembolization carries the risk of radioembolization-induced liver disease in the treatment of advanced hepatocellular carcinoma: safety and efficacy comparison to systemic therapy with atezolizumab/bevacizumab. *Cancers (Basel).* 2023;15(17):4274.
7. Ramalho M, Matos AP, AlObaidy M, Velloni F, Altun E, Semelka RC. Magnetic resonance imaging of the cirrhotic liver: diagnosis of hepatocellular carcinoma and evaluation of response to treatment - Part 1. *Radiol Bras.* 2017;50(1):38-47.
8. Wasan HS, Gibbs P, Sharma NK, et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. *Lancet Oncol.* 2017;18(9):1159-1171.
9. d'Abadie P, Walrand S, Goffette P, et al. Antireflux catheter improves tumor targeting in liver radioembolization with resin microspheres. *Diagn Interv Radiol.* 2021;27(6):768-773.
10. Titano JJ, Fischman AM, Cherian A, et al. End-hole versus microvalve infusion catheters in patients undergoing drug-eluting microspheres-TACE for solitary hepatocellular carcinoma tumors: a retrospective analysis. *Cardiovasc Intervent Radiol.* 2019;42(4):560-568.
11. Pasciak AS, McElmurray JH, Bourgeois AC, Heidel RE, Bradley YC. The impact of an antireflux catheter on target volume particulate distribution in liver-directed embolotherapy: a pilot study. *J Vasc Interv Radiol.* 2015;26(5):660-669.
12. TriSalus™ TriNav® Infusion System Instructions for Use.
13. TriSalus™ TriNav® LV Infusion System Instructions for Use.